REVIEW

3282  Hepatitis B and circadian rhythm of the liver
      Skrlec I, Talapko J

3297  Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy

3314  Crosstalk between dietary patterns, obesity and nonalcoholic fatty liver disease
      Ristic-Medic D, Bajerska J, Vucic V

MINIREVIEWS

3334  Application of intravoxel incoherent motion diffusion-weighted imaging in hepatocellular carcinoma

3346  Regulatory T cells and their associated factors in hepatocellular carcinoma development and therapy
      Zhang CY, Liu S, Yang M

3359  Single-incision laparoscopic surgery to treat hepatopancreatobiliary cancer: A technical review
      Chuang SH, Chuang SC

3370  Probiotics and postbiotics in colorectal cancer: Prevention and complementary therapy
      Kvakova M, Kamlarova A, Stofilova J, Benetinova V, Berkova I

3383  Interventional strategies in infected necrotizing pancreatitis: Indications, timing, and outcomes
      Purschke B, Bolm L, Meyer MN, Sato H

3398  Artificial intelligence in liver ultrasound
      Cao LL, Peng M, Xie X, Chen GQ, Huang SY, Wang JY, Jiang F, Cui XW, Dietrich CF

3410  Risk factors and diagnostic biomarkers for nonalcoholic fatty liver disease-associated hepatocellular carcinoma: Current evidence and future perspectives
      Ueno M, Takeda H, Takai A, Seno H

ORIGINAL ARTICLE

Basic Study

3422  Accumulation of poly (adenosine diphosphate-ribose) by sustained supply of calcium inducing mitochondrial stress in pancreatic cancer cells
      Jeong KY, Sim JJ, Park M, Kim HM
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3435</td>
<td>RING finger and WD repeat domain 3 regulates proliferation and metastasis through the Wnt/β-catenin signalling pathways in hepatocellular carcinoma</td>
<td>Liang RP, Zhang XX, Zhao J, Lu QW, Zhu RT, Wang WJ, Li J, Bo K, Zhang CX, Sun YL</td>
</tr>
<tr>
<td>3503</td>
<td>Novel index for the prediction of significant liver fibrosis and cirrhosis in chronic hepatitis B patients in China</td>
<td>Liao MJ, Li J, Dang W, Chen DB, Qin WY, Chen P, Zhao BG, Ren LY, Xu TF, Chen HS, Liao WJ</td>
</tr>
<tr>
<td>3514</td>
<td>Percutaneous transhepatic cholangiography vs endoscopic ultrasound-guided biliary drainage: A systematic review</td>
<td>Hassan Z, Gadour E</td>
</tr>
<tr>
<td>3524</td>
<td>Isolated gastric variceal bleeding related to non-cirrhotic portal hypertension following oxaliplatin-based chemotherapy: A case report</td>
<td>Zhang X, Gao YY, Song DZ, Qian BX</td>
</tr>
<tr>
<td>3532</td>
<td>Hepatitis B core-related antigen: Are we near a treatment endpoint?</td>
<td>Gupta T</td>
</tr>
</tbody>
</table>
ABOUT COVER
Editorial Board Member of World Journal of Gastroenterology, Govind K Makharia, MD, DM, DNB, Professor, Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India. govindmakharia@aiims.edu

AIMS AND SCOPE
The primary aim of World Journal of Gastroenterology (WJG, World J Gastroenterol) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING
The WJG is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports, Index Medicus, MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJG as 5.374; IF without journal self cites: 5.187; 5-year IF: 5.715; Journal Citation Indicator: 0.84; Ranking: 31 among 93 journals in gastroenterology and hepatology; and Quartile category: Q2. The WJG’s CiteScore for 2021 is 8.1 and Scopus CiteScore rank 2021: Gastroenterology is 18/149.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Wen-Wen Qi; Production Department Director: Xiang Li; Editorial Office Director: Jia-Ru Fan.

NAME OF JOURNAL
World Journal of Gastroenterology

ISSN
ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE
October 1, 1995

FREQUENCY
Weekly

EDITORS-IN-CHIEF
Andrzej S Tarnawski

EDITORIAL BOARD MEMBERS
http://www.wjgnet.com/1007-9327/editorialboard.htm

PUBLICATION DATE
July 21, 2022

COPYRIGHT
© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/gerinfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/gerinfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.f6publishing.com
Regulatory T cells and their associated factors in hepatocellular carcinoma development and therapy

Chun-Ye Zhang, Shuai Liu, Ming Yang

Abstract

Liver cancer is the third leading cause of cancer-related death worldwide with primary type hepatocellular carcinoma (HCC). Factors, including carcinogens, infection of hepatitis viruses, alcohol abuse, and non-alcoholic fatty liver disease (NAFLD), can induce HCC initiation and promote HCC progression. The prevalence of NAFLD accompanying the increased incidence of obesity and type 2 diabetes becomes the most increasing factor causing HCC worldwide. However, the benefit of current therapeutic options is still limited. Intrahepatic immunity plays critically important roles in HCC initiation, development, and progression. Regulatory T cells (Tregs) and their associated factors such as metabolites and secreting cytokines mediate the immune tolerance of the tumor microenvironment in HCC. Therefore, targeting Tregs and blocking their mediared factors may prevent HCC progression. This review summarizes the functions of Tregs in HCC-inducing factors including alcoholic and NAFLD, liver fibrosis, cirrhosis, and viral infections. Overall, a better understanding of the role of Tregs in the development and progression of HCC provides treatment strategies for liver cancer treatment.

Key Words: Hepatocellular carcinoma; Regulatory T cells; Alcoholic fatty liver disease; Non-alcoholic fatty liver disease; Treatment; Clinical trials

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Core Tip: Liver cancer is the third leading cause of cancer-related death worldwide. Hepatocellular carcinoma (HCC) is the primary type of liver cancer. Factors, including carcinogenic infection of hepatitis viruses, alcohol abuse, and non-alcoholic fatty liver disease (NAFLD), can induce HCC initiation and promote HCC progression. The prevalence of NAFLD accompanying the increased incidence of obesity and type 2 diabetes becomes the most increasing factor causing HCC worldwide. However, the benefit of current therapeutic options is still limited. Intrahepatic immunity plays critically important roles in HCC initiation, development, and progression. Regulatory T cells (Tregs) and their associated factors such as metabolites and secreting cytokines mediate the immune tolerance of the tumor microenvironment in HCC. Therefore, targeting Tregs and blocking their mediated factors may prevent HCC progression. A better understanding of the role of Tregs in intrahepatic immunity is helpful to develop novel HCC treatment options.

Citation: Zhang CY, Liu S, Yang M. Regulatory T cells and their associated factors in hepatocellular carcinoma development and therapy. World J Gastroenterol 2022; 28(27): 3346-3358
URL: https://www.wjgnet.com/1007-9327/full/v28/i27/3346.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i27.3346

INTRODUCTION

Liver cancer is the third leading cause of cancer-related death worldwide with 8.3% of death ratio, following lung and colorectal cancers[1]. The most common type of primary liver cancer is hepatocellular carcinoma (HCC) and the second type is cholangiocarcinoma[2]. Factors, including carcinogens (e.g., aflatoxin B1), infection of hepatitis viruses, alcohol abuse, and non-alcoholic fatty liver disease (NAFLD), can induce HCC and promote HCC progression[3-5]. In addition, accompanying the increasing incidence of obesity and type 2 diabetes (T2D), NAFLD becomes an increasing factor that causes HCC worldwide[6,7].

Surgical resection is a curative treatment option for the early stage of HCC. However, most cases in HCC were found in the late stage. In addition, other minimally invasive local therapies, such as radiofrequency ablation and microwave ablation, and systemic therapy, such as tyrosine kinase inhibitors, are treatment options for patients who are not suitable for surgery[8]. Furthermore, immunotherapy by targeting checkpoint inhibitors [e.g., anti-programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) antibodies] shows benefits against advanced HCC in the clinic. A combination treatment by blocking both PD-L1 (e.g., atezolizumab) and vascular endothelial growth factor (VEGF) (e.g., bevacizumab) is one of the best first-line treatments for advanced HCC[9]. Other potential immunotherapy options including T cell-mediated therapy such as chimeric antigen receptor-engineered T cells[10-12], peptide-based vaccines[13-15], and micro ribonucleic acids (miRNAs)-mediated therapies[16], are undergoing investigations for HCC treatment.

Intrahepatic immunity including both innate and adaptive immune responses plays pivotal roles in the development and progression of HCC, especially for T cells[17]. Among them, the imbalance between effector CD4 and/or CD8 T cells and regulatory T cells (Tregs) induces immunotolerance and promotes HCC progression[18,19]. Factors impacting the balance of effector T cells and Tregs include gut microbiota, transforming growth factor-beta (TGF-β), and treatments such as trans-arterial chemoembolization[18-20], etc. The expression of cytokines such as interleukin (IL)-2, IL-5, interferon (IFN)-γ was increased with an increased ratio of cytotoxic T lymphocytes (CTLs)/Tregs with the treatment of Lenvatinib, a multiple kinase inhibitor, while the expression of T-cell immunoglobulin mucin-3 (Tim-3) and CTL-associated antigen-4 (CTLA-4) was decreased on Treg cells[21]. Therefore, modulating the Treg frequency and the expression of related cytokines are critically important for anti-tumor immunotherapy.

In this review, functions of Tregs on HCC causing factors such as alcoholic liver disease (ALD), NAFLD, liver fibrosis, and cirrhosis are discussed. In addition, molecules mediated Treg functions and therapeutic options by targeting Tregs are summarized. Moreover, clinical trials by targeting Tregs to modulate immune response were analyzed.

TREGS IN CHRONIC LIVER DISEASE

Tregs in ALD

As immunosuppressive cells, Tregs play a pivotal role in chronic liver diseases, including ALD. For example, chronic-binge alcohol exposure in C57BL/6 mice induced the reduction of Treg cells, but increased T helper 17 cells (Th17) cells and the production of IL-17[22]. Treatment with ginsenoside F2
can ameliorate ALD by increasing the frequency of Foxp3+ Tregs and decreasing IL-17-producing Th17 cells compared to control groups[23]. However, the molecular mechanism of how Tregs impact the progression of ALD except for modulation of liver inflammation remains unclear.

Tregs in NAFLD and nonalcoholic steatohepatitis
The balance Th17 cells/Tregs plays an essential role in metabolic diseases by regulating immune response and glucose and lipid metabolism[8]. The lower Treg (forkhead box P3+/FOXp3+) and higher Th17 cell (IL-17-producing) numbers were found in portal or periportal tract in livers of adult NAFLD patients, whereas more Tregs were shown in pediatric NAFLD patients[24]. In addition, severe liver inflammation was positively associated with intralobular expression of FOXP3 in pediatric patients but was positively associated with higher expression of IL-17 and lower expression of FOXP3 in adult patients, indicating the role of Tregs in NAFLD is age-dependent. Intrahepatic imbalance of Th17/Treg cells promotes the progression of NAFLD, accompanying higher expression of inflammatory cytokines such as IL-6, IL-17, and IL-23 in both serum and liver[25]. Feeding a high-fat diet (HFD) can impact the balance of Th17/Treg cells and Th1/Th2 cells of CD4 T cells in mesenteric lymph nodes (MLN). In addition, those CD4 T cells can potentially migrate into the liver to promote liver inflammation to result in NAFLD progression[26]. The effects of CD4 T cells in MLN on liver inflammation and fat accumulation can be ameliorated by administration of antibiotics and probiotics, indicating an important role of gut microbiota in NAFLD pathogenesis[26].

Dywicki et al[27] showed intrahepatic Tregs were increased in high-fat high-carbohydrate (HF-HC) diet-induced nonalcoholic steatohepatitis (NASH) in BALB/c mice. In addition, depletion of adaptive immunity aggregated HF-HC diet-induced NASH in recombination activating γ-knockout BALB/c mice. Although Tregs showed an anti-inflammation effect in ALD[23], adoptive transfer of Tregs increased steatosis and serum level of alanine aminotransferase (ALT), indicating that Tregs enhance the progression of NAFLD[27]. Another study also showed that increasing Tregs in subcutaneous adipose tissue induced by adoptive transfer of Tregs from healthy C57BL/6 mice to high-fat HFD (HHF-HFD)-fed mice increased hepatic steatosis during NAFLD development[28].

Mechanistically, the formation of neutrophil extracellular traps during NASH progression can induce Treg differentiation from naïve CD4 T cells, which is dependent on Toll-like receptor 4 (TLR-4) and involved in NASH-HCC progression[29].

Tregs in liver fibrosis and cirrhosis
Progression of chronic liver disease, including ALD and NAFLD, can promote the development of liver fibrosis and its advanced stage liver cirrhosis. However, there are no currently available therapies that can treat or reverse liver cirrhosis. Deng et al[30] reported that co-infusion with human amniotic mesenchymal stromal cells (hAMSCs) and Tregs can prevent mild liver fibrosis. Tregs play a critical role in the secretion of hepatocyte growth factor (HGF) and cell differentiation of hAMSCs.

Furthermore, an imbalance of Th17 cells/Tregs was also shown in cirrhotic patients with hepatitis B virus (HBV) infection. The frequency of Tregs was reduced in peripheral blood, while the frequency of Th17 cells was increased, resulting in a decreased Treg/Th17 ratio as a potential diagnostic marker for decompensated liver cirrhosis[31]. Another study also showed that the frequencies of both Tregs and Th17 cells were increased in the blood of patients with HBV infection and cirrhotic livers but with a higher extent in Th17 cells, resulting in an increased ratio of Th17/Treg, compared to the control group[32]. In addition, the mRNA levels of proinflammatory cytokines IL-1β, IL-6, and tumor necrosis factor (TNF)− were increased in the liver and liver inflammation was positively associated with intralobular expression of FOXP3 in adult patients. The lower Treg (forkhead box P3+) and increasing expression of IL-17 and FOXP3 were associated with a poor prognosis of HCC patients[33]. Moreover, the frequency of Tregs in blood and plasma levels of IL-35 were increased and positively correlated with tumor immunity and enhancement of HCC metastasis[33]. In addition, the serum levels of TGF-β and IL-10 in HBV-infected liver and cirrhotic liver compared to healthy controls. Another study also showed that HBV infection can induce IL-8/C-X-C motif chemokine receptor 1 (CXCR1) and chemokine receptor 2 (CXCR2) signaling to provoke Treg polarization, resulting in suppression of anti-tumor immunity and enhance of HCC metastasis[33].

Tregs in HCC
A meta-analysis showed that a higher infiltration of CD3 T cells, CD8 T cells, and natural killer cells was associated with better overall survival (OS), disease-free survival (DFS), and recurrence-free survival (RFS). In contrast, a higher infiltration of Tregs and neutrophils indicated lower OS and DFS[35]. Another report also showed that an increase of Tregs or a decrease of M1 macrophages (proinflammatory phenotype) were associated with a poor prognosis of HCC patients[36]. C-C chemokine receptor type 4 (CCR4)+ Tregs are predominant Tregs that are recruited in tumor tissue of HCC associated infection of hepatitis viruses, which is associated with HCC resistance to sorafenib treatment[37]. The frequency of CD127+, CD25+, CD4+, Tregs was increased significantly in the peripheral venous blood of HCC patients compared to healthy controls[38]. In addition, the serum levels of TGF-β1 and IL-10 in HCC patients were positively associated with the Treg population in the blood, which were decreased post-operation and chemotherapy treatments. C-C motif chemokine ligand (CCL) 5 expression on circulating tumor cells in HCC patients can attract Tregs to induce an immunosuppressive environment, one of the mechanisms for CTC escaping immune surveillance[39].
The expression of immune checkpoint proteins in the HCC microenvironment impacts Tregs and antitumor immunity. PD-L1/neutrophils, Tregs, and neutrophil to lymphocyte ratio were significantly increased in peripheral blood of patients with poorly differentiated HCC with a worse prognosis compared to that in patients with highly-moderately differentiated HCC. Zhou et al.[41] reported that tumor-associated neutrophils can induce the infiltration of the macrophages and Tregs from HCC mice or patients via producing CCL2 and CCL17, resulting in HCC progression and resistance to sorafenib. CTLA-4 on Tregs in HCC impacts dendritic cell function by downregulating CD80/CD86 on dendritic cells (DCs).[42] Therefore, blockade of CTLA-4 in HCC can improve DC-mediated anti-tumor immunity.

Treatment with tivozanib, a tyrosine kinase inhibitor, can induce Tregs by inhibiting receptor tyrosine kinase c-Kit (CD117)/stem cell factor (SCF) axis and increased CD4\(^+\)PD-1\(^+\)T cells, resulting in a significant improvement in OS of HCC patients.[43] Treatment with Lenvatinib also can inhibit IL-2 mediated Treg differentiation except for decreasing PD-L1 expression in HCC cells.[44] Overall, the balance between Tregs with other T cells plays a vital in liver diseases, including the initiation and progression of HCC (Figure 1).

Furthermore, alteration of intrahepatic immunity is associated with HCC prognosis and treatment (Figure 2). An increase of Tregs, Th2, and Th17 T cells, as well as M2 macrophages, is usually and positively associated with HCC progression in patients, whereas an abundance of CD8 T cells, Th1 T cells, and M1 macrophages is associated with HCC therapy and good prognosis for HCC patients[45]. Single-cell RNA sequencing technologies have been applied to investigate the immune landscape of HCC samples to illustrate the subtypes of immune cells in HCC and their gene expressing profiles, as well as immune cell interactions, such as DCs with Tregs or CD8 T cells[46].

### IMPORTANT MOLECULES MEDIATED TREG FUNCTION AND METABOLISM

**HIF-1α**

Hypoxia-inducible transcription factors (HIFs) regulate cell metabolism, proliferation, and migration in low oxygen or hypoxic environment, as well as angiogenesis.[47] It has been reported that the expression of HIF-1 alpha (HIF-1α) was higher in HCC tissues compared to that in corresponding adjacent tissues. In addition, overexpression of HIF-1α was associated with poor outcomes of HCC in human patients.[48] Chronic intermittent hypoxia can promote NASH progression via regulating the balance of Th17/Treg by inducing the expression of HIF-1α[49].

**Gal-9**

Tregs can be subclassified into inflamed-tissue related memory Tregs (mTregs) and non-related resting Treg (rTregs). During HBV infection, mTregs were increased accompanying liver inflammation and liver injury evidenced by an increase of serum ALT level, but not rTregs.[50] The S-type lectin galectin-9 (Gal-9) was increased in the HBV-infected liver, contributing to T cell depletion and exhaustion by binding Tim-3.[51] For example, activation of Gal-9/Tim-3 signaling in concanavalin A-induced mouse hepatitis suppressed the induction of effector T (Teff) cells and the production of IFN-γ.[52] In addition, the Gal-9/Tim-3 signaling pathway plays an important role in the expansion of mTregs[50].

**GDF15**

The expression of growth differentiation factor 15 (GDF15) was positively related to the frequency of Tregs in HCC. GDF15 can promote the suppressive effect of natural Tregs via binding with its unrecognized receptor CD48 on T cells to inhibit the function of homology and U-box containing protein 1, which can degrade FOXP3.[53] Thus, neutralizing GDF15 by an antibody can eradicate HCC and enhance anti-tumor immunity.

**microRNAs**

Hepatic expression of microRNA-195 (miR-195) was reduced in NAFLD development, accompanying an increased ratio of Th17/Treg ratio in the blood, as well as the expression IL-17, CD40, and TNF-α in rat liver.[54] Overexpression of miR-195 can maintain the balance of Th17/Treg to ameliorate NAFLD and liver inflammation. Many miRNAs can regulate Th17/Treg cell balance in NAFLD such as miR-29c via interacting with insulin-like growth factor binding protein 1 (IGFBP1)[55]. In addition, other microRNAs such as miR-155[56,57], miR-423-5p[58], and miR-1246[59] play important roles in modulating the balance of Tregs with Th17 cells and their functions in liver disease.

**TLRs**

Activation of TLR signaling pathway can suppress the effect of Tregs on adaptive immune response, which is in part dependent on microbial production-induced expression of IL-6.[60] TLR9-deficiency increased the frequency of Treg cells in the intestine, resulting in a decrease of IL-17 and IFN-γ producing Teff cells.[61] The imbalance of Treg/Teff cells compromised immune response to oral
The imbalance of regulatory T cells and effector T cells promotes the progression of chronic liver diseases and hepatocellular carcinoma. Chronic liver diseases such as alcoholic liver disease and non-alcoholic fatty liver disease induced by factors such as alcohol abuse and high-fat diet, respectively, can induce liver fibrosis, cirrhosis, and even hepatocellular carcinoma. The imbalance of regulatory T cells with T helper 17 cells or CD8 T cells is involved in the pathogenesis of liver inflammation, fibrosis, and cancer progression. ALD: Alcoholic liver disease; HCC: Hepatocellular carcinoma; NAFLD: Non-alcoholic fatty liver disease; Treg: Regulatory T cells; Th: T helper.

infection, which can be reversed by reconstitution of gut flora deoxyribonucleic acid (DNA)\[61\]. In addition, the antibiotic treatment caused gut microbiota dysbiosis and recapitulated TLR9 deficiency-induced impaired immune response.

Yes-associated protein (YAP)
Yes-associated protein (YAP), a coactivator and a corepressor of the Hippo signaling pathway, plays a vital role in Tregs in vivo and in vitro[62]. Blocking YAP-mediated activation of activin can improve anti-tumor immunity via regulating TGF-β/Smad[62]. Similarly, blockage of TGF-β signaling can compromise Treg function to improve anti-tumor immune response[63], which may expand the population of quiescent Tregs, CD4+CD25-Foxp3+.

The above-mentioned molecules can modulate Treg metabolism and function as potential molecular targets for HCC treatment. In addition, modulation of these molecules can potentially recover the balance of Tregs with other tumor-infiltrating immune cells to activate anti-tumor immunity (Figure 3).

TREATMENT OPTIONS

Modulation of microRNAs
Administration of miR-26a can reduce the frequency of Tregs and the concentrations of alpha-fetoprotein, des-gamma carboxyprothrombin, and VEGF in Balb/c mice with diethylnitrosamine-induced HCC[64]. The suppressive effects of miR-26a on HCC growth and angiogenesis are mediated by targeting IL-6/signal transducer and activator of transcription 3 (Stat3) signaling[65] and HGF/HGF receptor (HGF/c-Met) signaling[66], respectively. In addition, miR-26a inversely regulated the expression of F-box protein 11 (FBXO11), which was upregulated and played an oncogenic role in HCC [67].

Adoptive transfer of cells
Adoptive transfer of Tregs attenuated triptolide-induced liver injury, while depletion of Tregs showed the opposite effect, indicating that Tregs contribute to the progression of liver injury[68]. Another study showed that adoptive transfer of hepatic stellate cell (HSC)-stimulated Tregs can significantly decrease liver injury in mice with autoimmune hepatitis by inducing the balance of Treg/Th17 ratio[69]. In addition, the adoptive transfer of HSCs promoted the differentiation of Tregs and decreased Th17 cells,
Figure 2 The alteration of intrahepatic immunity predicts the prognosis of hepatocellular carcinoma patients. Usually, an increase of regulatory T cells, Th helper (Th) 2 cells, and Th17 cells, as well as M2 macrophages is positively associated with hepatocellular carcinoma (HCC) progression in patients, whereas an abundance of CD8 T cells, Th1 T cells, and M1 macrophages is associated with HCC therapy and good prognosis for HCC patients. HCC: Hepatocellular carcinoma; Treg: Regulatory T cells; Th: T helper.

Figure 3 Factors mediated the imbalance of regulatory T cells/effector T cells. Factor such as Hepatitis B virus, gut microbiota, and non-alcoholic fatty liver disease, as well as hepatocellular carcinoma tumor cells, can modulate several important molecules produced in the liver. Alteration of these molecules has been associated with the change of frequency and/or function of regulatory T cells in chronic liver disease, resulting in an imbalance of regulatory T cells/effector T cells. HCC: Hepatocellular carcinoma; HBV: Hepatitis B virus; NAFLD: Non-alcoholic fatty liver disease; Teff: Effector T cells; Treg: Regulatory T cells; GDF: Growth differentiation factor; HIF: Hypoxia-inducible transcription factors; Gal: Galectin; miR: micro ribonucleic acid; TLR: Toll-like receptor; YAP: Yes-associated protein; TGF-β: Transforming growth factor-beta.

resulting in amelioration of liver injury[70]. Deng et al[30] reported that co-infusion with hAMSCs and Tregs can prevent mild liver fibrosis. Tregs play a critical role in the secretion of HGF and cell differentiation of hAMSCs.
Inhibiting GDF15 function by a neutralizing antibody can effectively suppress the effect of miR-26a on HCC growth and angiogenesis. Dual therapies increased CD8 T cell infiltration and activation, reducing Tregs and inducing balance in the ratio of Treg and Th17 cells to reduce alcoholic-induced liver injury.

Probiotic treatment regulated T-cell differentiation in the gut by reducing Th17 polarization and increasing the differentiation of anti-inflammatory Treg cells, by increasing the abundance of beneficial bacteria, such as *Prevotella* and *Oscillibacter*. This study also showed that probiotic treatment regulated T-cell differentiation in the gut by reducing Th17 polarization and increasing the differentiation of anti-inflammatory Treg cells.

**Modulation of gut microbiota**

Depletion of Tregs in the intestine caused an increase in the abundance of *Firmicutes* and intestinal inflammation[71]. Supplementation of *Lactobacillus rhamnosus* GG or its culture supernatant can ameliorate chronic alcohol-induced liver injury by reducing TNF-α expression via inhibition of TLR4- and TLRS-mediated hepatic inflammation[72], as well as amelioration of intestinal barrier integrity and suppression of alcohol-induced endotoxemia[73]. In addition, the culture supernatant can balance the ratio of Treg and Th17 cells to reduce alcoholic-induced liver injury[22].

Treatment with Prohep, a novel probiotic mixture, significantly inhibited the HCC growth compared to the control group, resulting in an abundant of beneficial bacteria, such as *Prevotella* and *Oscillibacter*[74]. This study also showed that probiotic treatment regulated T-cell differentiation in the gut by reducing Th17 polarization and increasing the differentiation of anti-inflammatory Treg cells.

**Blockade of immune checkpoints**

Dual anti-PD-1/VEGFR-2 therapy increased CD8 T cell infiltration and activation, reduced Tregs and infiltration of CCR2 monocytes, as well as the phenotype of tumor-associated macrophages (the M1/M2 ratio) in HCC tissue[75]. Another study also showed that Treg-mediated inhibition of IFN-γ production and cytotoxicity of CD8 T cells can be partially reduced by anti-PD-1 and anti-PD-L1 antibodies in HCC tissue[76].

Treg depletion-mediated by anti-CTLA-4 monoclonal antibody (clone 9H10) restored the function of tumor antigen-specific CD8 T cells, with a synergistic effect with anti-PD-1 treatment[77].

**Other treatments**

CCR4 expression in Tregs accompanied with an increased expression IL-10 and IL-35, resulting in suppression of CD8 T cells and HCC progression. Administration of a CCR4 antagonist or N-CCR4-Fc, a
neutralizing pseudo-receptor that can block Tregs accumulation in HCC, can enhance therapeutic efficacy to PD-1 blockade and sorafenib[37]. Treg depletion induced by anti-CCR4 antibody (mogamulizumab), in combination with anti-PD-1 antibody (nivolumab) showed antitumor activity and increased CD8+ T cell infiltration[78].

Treatment with resveratrol, a natural phenol, can inhibit H22 (a mouse HCC cell line)-induced orthotopic HCC tumor growth via decreasing the frequency of CD8+/CD122+ Tregs and M2-like macrophages in mice[79].

Ren et al[80] reported that Tregs were further increased in HCC patients compared to healthy and cirrhosis controls, as well as in HCC patients with Barcelona clinic liver cancer (BCLC) stage C compared to that in HCC patients with BCLC stage B. The authors also showed that treatment with microparticles-transarterial chemoembolization dramatically decreased Treg cell proportion at 1-2 wk post-treatment. Overall, the treatment options for HCC associated with Treg regulation were summarized in Table 1.

### CLINICAL TRIALS

Tregs display multiple roles in the development and progression of HCC. The ratio of Treg/Th17 cells in peripheral blood can be applied to monitor immune tolerance as immune markers in liver transplantation[81]. The balance of Treg/Th17 cells or other effector T cells is essential for suppressing autoimmune diseases and cancers[82]. Therefore, treatments including diverse immunomodulatory therapies can regulate Tregs to enhance the antitumor immune response. In Table 2, potential therapies in clinical trials were summarized. Treatments including infusion of Tregs[83-85] and mesenchymal stalkom cells (MSCs)[86], vaccines[87-89], and kinase inhibitors[90].
CONCLUSION

Tregs modulate the intestinal and intrahepatic immune response, contributing critically important roles in the gut-liver axis. Functional changes of Tregs are involved in the pathogenesis of chronic liver diseases, such as ALD and NAFLD, causing factors for HCC. Several important molecules investigated in recent studies are summarized and targeting them may potentially treat HCC by modulating Treg function and/or frequency. Clinical trials are undergoing to further explore the new treatments for HCC, which modulate the function of the frequency of Tregs. In the future, multi-omic analysis including metabolic and proteomic data for Treg metabolism and function during the progression of HCC is critical to illustrate the underlying mechanisms of Tregs in HCC pathogenesis and find out new therapeutic targets.

FOOTNOTES

Author contributions: Zhang CY, Liu S, and Yang M designed and collected data, wrote, revised, and finalized the manuscript; all authors contributed equally, and shared the first authorship.

Conflict-of-interest statement: There are no conflicts of interest to report.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: United States

ORCID number: Chun-Ye Zhang 0000-0003-2567-029X; Shuai Liu 0000-0001-9695-2492; Ming Yang 0000-0002-4895-5864.

S-Editor: Chen YL
L-Editor: A
P-Editor: Chen YL

REFERENCES

Zhang CY et al. Role of Tregs in HCC


Zhang CY et al. Role of Tregs in HCC

2398 [PMID: 33653774 DOI: 10.1158/0008-5472.CAN-20-3453]


Zhang CY et al. Role of Tregs in HCC

10.1139/cjpp-2018-0467


77 Lee JC, Mehdizadeh S, Smith J, Young A, Mufazalov IA, Mowerey CT, Daud A, Bluestone JA. Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. Sci Transl Med 2020; 5 [PMID: 33008914 DOI: 10.1126/scitranslmed.aba0759]


Zhang CY et al. Role of Tregs in HCC


Kalathil SG, Hudson A, Barbi J, Iyer R, Thanavala Y. Augmentation of IFN-γ+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy. JCI Insight 2019; 4 [PMID: 31391334 DOI: 10.1172/jci.insight.130116]